Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Survodutide Fatty Liver Disease Treatment Normalizes Liver Fat in Phase 3
Boehringer Ingelheim presented Phase 3 trial data showing survodutide normalized liver fat in 61% of patients with fatty liver disease (MASLD).
Travere Therapeutics Signs $1.1B Licensing Deal with Everest Medicines
Travere Therapeutics gains an exclusive license to Everest Medicines' oral BTK inhibitor civorebrutinib for rare immune kidney diseases.
UCSF Selects Filament Health Psilocybin for Alzheimer's Studies
UCSF chooses Filament Health's botanical psilocybin candidate PEX010 to explore structural markers and indicators in early-stage Alzheimer's disease.
Lonza Enhances Biologics Pipeline with GS Ori-Go Vector Platform
Lonza expands its biologics preclinical development portfolio with GS Ori-Go vector technology, reducing DNA-to-IND development timelines.
FDA Issues Warning Letter to Medline Over Bacterial Contamination
Medline Industries faces FDA regulatory actions after inspectors discover repeat bacterial contamination issues at its Waukegan manufacturing facility.
New Topical 4-Aminopyridine Gel Accelerates Burn Wound Healing
Researchers develop a breakthrough topical 4-aminopyridine (4-AP) gel that significantly accelerates burn wound healing and skin regeneration.
PET Imaging Reveals Synaptic Loss in Multiple Sclerosis Progression
Researchers at SNMMI 2026 unveiled a breakthrough SV2A PET imaging technique to measure spinal cord synaptic density and track multiple sclerosis.
FDA Approves Orally Disintegrating Cavhanza Tablets for Ph+ CML
Cycle Pharma's Cavhanza (nilotinib ODT) won FDA approval for Ph+ CML, allowing safe co-administration with PPIs and H2RA acid reducers.
Merck's Calderasib Wins FDA Breakthrough Therapy Tag for Lung Cancer
The FDA granted Breakthrough Therapy designation to Merck’s calderasib (MK-1084) plus Keytruda for first-line KRAS G12C-mutant metastatic NSCLC.
First-in-Class Mitochondria Cancer Drug Gamitrinib Enters Phase 1 Trial
In a new clinical trial evaluated at ASCO 2026, the first-in-class mitochondria-targeted cancer drug gamitrinib demonstrated strong safety profiles.
FDA vs EMA: Study Shows US Approves More Orphan Drugs for Cancer
A cross-sectional study reveals the US FDA approves more orphan drugs with specific cancer and pediatric indications compared to Europe’s EMA.
Landmark Study Stops Pancreatic Cancer Before It Starts With KRAS Drugs
A breakthrough preclinical study shows that experimental KRAS inhibitors can eliminate microscopic precancerous lesions, preventing pancreatic cancer.
4
5
6
7
8
9
10
11
12
